Clinical and cost effectiveness of percutaneous coronary intervention for patients with chronic coronary artery disease during overnight hospitalization

Aim. To evaluate cost effectiveness of coronary endovascular treatment in patients with stable IHD during “one-night” hospitalization. Materials and methods. Using the cost-minimization analysis direct medical cost of coronary endovascular treatment in patients with stable IHD during the “one-night” hospitalization was compared with the “classic” hospitalization. Results. The most cost-effective strategy for hospitalization of patients for transcutaneous coronary intervention (TCI) with stenting was the “one-night” hospitalization. Differences in direct medical costs (DMC) were statistically significant (p=0.01) in favor of the patient group hospitalized for one night. Conclusion. The “one-night” hospitalization plan for patients with stable IHD to undergo TCI with stenting increases the cost-effectiveness due to the decreased number of days of stay in the hospital and the associated decrease in cost of in-patient maintenance, which resultes in considerable financial savings (А between the hospitalization plans was 21.2% in favor of the “one-might” hospitalization). This А indicates high cost effectiveness of the selected approach.

клинико-экономическая эффективность, прямые медицинские затраты, госпитализация на «одну ночь», чрескожное коронарное вмешательство, cost effectiveness, direct medical costs, overnight hospitalization, transcutaneous coronary intervention

1. Гиляревский С. Р., Орлов В.А. Использование анализа эффективности лечения для принятия клинического решения в кардиологии. Кардиология. 1997; 37 (9): 70-80.

2. Drummond M/F. Resource allocation decisions in health care: a role for quality of life assessments? J Chronic Dis. 1987: 40 (6): 60 5-1 9.

3. O’Brien B. Principles of economic evaluation for health care programs. J Rheumatol. 1995; 22 (7): 1399-402.

4. Шаповалова M.А., Корецкая Л.P. Организация стационарной медицинской помощи в неврологической практике как медикоэкономическая проблема. Кубанский научный медицинский вестник. 2011; (2): 183-6.

5. Flack J.M., Novikov S.V., Ferrario C.M. Benefits of adherence to anti-hypertensive drug therapy. Eur Heart J. 1996; 17 Suppl A: 16-20.

6. Авксентьева М.В., Воробьев П.А., Герасимов В.Б., Горохова С.Г. Экономическая оценка эффективности лекарственной терапии (фармакоэкономический анализ). - М.: ООО «Медикотехнологическое предприятие «Ньюдиамед»; 2000. 80 с.

7. Avxentieva M., Vorobjov P., Sura M. PCV38 Costs of myocardial infarction treatment in Russian Federation. Value in Health. 2004; 7(6): 696-7. DOI: 10.1016/S1098-3015 (10) 65820-2

8. Maron D.J. Nonlipid primary and secondary prevention strategies for coronary heart disease. Clin Cardiol. 1996; 19 (5): 419-23.

9. Синьков М.А., Ваккосов К.М., Шилов А.А., Синьков А.А., Ганюков В.И., Барбараш О.Л. и др. Оценка клинико-экономической эффективности применения методики измерения фракционного резерва кровотока в лечении больных ИБС. Комплексные проблемы ССЗ. 2016; 5 (4): 33-8.

10. Walley T. Drugs, money and society. Br J Clin Pharmacol. 1995; 39 (4): 343-5.

11. Doubilet P., Weinstein M.C., McNeil B.J. Use and misuse of the term «Cost Effective» in medicine. New England Journal of Medicine. 1986; 314 (4): 253-6. DOI: 10.1056/NEJM198601233140421

12. Jönsson B. Measurement of health outcome and associated costs in cardiovascular disease. Eur Heart J. 1996; 17 Suppl A: 2-7.

13. Bowling A. Research methods in health: investigating health and health services. 3. ed., repr. -Maidenhead: Open Univ. Press; 2010. 525 с. ISBN: 978-0-335-23364-9

14. Erhardt L., Ball S., Andersson F., Bergentoft P., Martinez C. Cost effectiveness in the treatment ofheart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics. 1997; 12 (2 Pt 2): 256-66.

15. Sheffield R.E., Sullivan S.D., Saltiel E., Nishimura L. Cost comparison of rcombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Annals of Pharmacotherapy. 1997; 31 (1): 15-22. DOI: 10.1177/106002809703100101